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A commentary on
Vitamin D and pancreatic cancer: a pooled analysis from the pancreatic cancer case-control
consortium
by Waterhouse M, Risch HA, Bosetti C, Anderson KE, Petersen GM, Bamlet WR, et al. Ann Oncol
(2015) 26:1776–83. doi:10.1093/annonc/mdv236
Waterhouse et al. criticized the association between vitamin D intake and the prevention of
pancreatic cancer (1), an association that has been thoroughly reviewed in recent years (2, 3). Yet,
randomized controlled clinical trials (RCTs) very rarely produced encouraging and reliable results
on the field (4–7). Negative evidence in animal models and experimental studies (8, 9) should
suggest that the chemopreventive role of 1,25(OH)2D3 deserve particular attention when dietary
vitamin D3 is considered (10). Best correlations were reported on vitamin D3 deficiency and cancer
malignancy (11–14) or on frequent dietary intake of vitamin D3 and tumor prevention (15). The
chemopreventive role might closely depend on plasma bioavailability of 25(OH)D3 and genetic
polymorphism of vitamin D receptor (VDR) (16, 17). Physicians are asking whether vitamin D3
supplementation may really contribute in preventing cancer (18, 19) and, at the same time, they
suggested recommendations to fortify foods with supplemented vitamin D3, to achieve optimal
levels of plasma 25(OH)D3 (20, 21).
Waterhouse et al. showed that cancer risk increased with higher levels of vitamin D intake,
although they did not exclude the possibility that vitamin D obtained through ultraviolet exposure
has a beneficial effect (1). In the future, 25(OH)D3 may become ofmajor importance in assessing the
role of the plasmatic content of vitamin D3 to prevent chronic diseases and cancer. Dietary vitamin
D3 exhibited the same anti-cancer activity than 1,25(OH)2D3 in mice (9), a chemically modified
form of 25(OH)vitD3 exerts a chemotherapeutic effect on neuroblastoma xenograft mouse model
(22), an imbalance in plasma availability of 25(OH)D3 is considered a risk factor for carcinoma
(23) and 25(OH)D3, likewise 1,25(OH)2D3, exerts an anti-inflammatory effect (24–26). Most of
the recent evidence should suggest that plasma level of 25(OH)D3 has a fundamental role in
warranting protection against chronic immune disorders and cancer (27). However, any approach to
enhance 25(OH)D3 bioavailabilitywith diet does not appear sufficient to improve vitaminD3-related
outcome, due to genetic variability within the population (28). This evidence may appear therefore
quite discouraging. Physicians are wondering how to focus onto vitamin D3 dietary intake to
prevent chronic immune disorders and cancer. Yet, a proper determination of plasmatic 25(OH)D3
metabolites is highly recommended (29, 30). Clinical chemists have some difficulty in evaluating
plasmatic 1,25(OH)2D3, particularly because it is rapidly degraded by 24-hydroxylases. Conversely,
25(OH)D3 biochemical activity should be attributed fundamentally to the 1-α-hydroxylated form,
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TABLE 1 | Flow chart of vitamin D dietary evaluation.
Pre-analytical stage
a) The population undergoing vitamin D3 supplementation: this point should be addressed by considering the main geographical area and whether population is coming
from developing or industrialized countries (this fact should focus on the dietary habit), their sex, their age
b) Genetic polymorphism and mutational analysis: particular genetic polymorphism for VDR should be highlighted (48–50). Moreover, genetic mutations for P450
cytochromes (particularly for CYP24A1) should be investigated (51, 52)
c) Metabolic homeostatic balance: particular importance should be given to the metabolic homeostatic machinery held by the subject prior to his intake of vitamin D3
(calcidiol level, presence of insulin resistance or metabolic syndrome, metabolic markers, etc.)
d) Diet survey: depending on the diet habit and life style, vitamin D3 supplementation might be accordingly adjusted, for a better performance
Analytical stage
e) Data on vitamin D3 availability: pharmacokinetics of vitamin D3, particularly when in association with chemopreventive drugs (53) should be known. A proper dosage
of plasmatic calcidiol should be performed. A reappraisal on calcitriol determination should be conducted
Post-analytical stage
f) Prospective studies and epidemiology: further detailed studies on the association between vitamin D3 dietary intake and cancer development should give a sound
contribution for the comprehension of the chemopreventive role of vitamin D3
yet actually a more complex mechanism, involving multiple
enzyme activity by P450 cytochromes and different metabolites,
has been recently reviewed in Ref. (31). This should oblige nutri-
tionists to be more cautious about the role of vitamin D3 sup-
plementation in cancer prevention. Active vitamin D3 is a short-
lived, potent hormonal molecule, whose efficacy seems to depend
on the homeostatic level of circulating and available 25(OH)D3.
The activity of the 25(OH)D3, is increased principally by the
action of CYP27B1 but recent evidence has interestingly reported
that a synthetic analog of 25(OH)D3, i.e., 5-hydroxy-16-ene-23-
yne-D3, is neither modulated by CYP27B1 nor by CYP24A1 and
expressed a potent anti-proliferative effect likewise 1,25(OH)2D3
(32). Furthermore, the use of synthetic analogs of 1,25(OH)2D3
appears quite promising in this field (33). Further, RCTs are
needed to shed a light on the availability of newly introduced
synthetic active forms of vitamin D3 for cancer prevention. The
evidence should suggest that a possible way to enhance the anti-
cancer activity of vitamin D3 is to increase 1,25(OH)2D3 effect
by reducing the inhibitory action of CYP24A1, with molecules
such as KD-35 or 4,5,6,7-tetrabromobenzimidazole (TBBz). This
apparently simplistic point of view appeared quite encouraging
(34, 35).
There are very few reports suggesting the possibility, through
dietary intake, to improve the activity of 1,25(OH)2D3 as an
immune cytokine and/or an hormone. CYP24A1 inhibitors, such
as the isoflavone genistein, could be theoretically assumed with
diet and they might potentiate the effect of 1,25(OH)2D3 in the
immune response against cancer, although further randomized
controlled trials are requested (36, 37).
Therefore, how to perform a correct dietary recommendation
to promote vitamin D3 as a possible chemopreventive molecule?
Western diet might induce or promote tumors, particularly when
deficient or lacking vitamin D3 (38, 39). This should suggest why
most of Western populations, living in industrialized countries,
are often vitamin D3 deficient. In this perspective, the initial
concern is to establish the proper dietary supplementation of vita-
min D3, to achieve an optimal plasmatic level of 25(OH)D3. How-
ever, the correct supplementation of vitamin D3 should depend
on sex and age, dietary habits, level of 25(OH)D3, geograph-
ical areas, individual’s gut microflora, and genetics of vitamin
D3 metabolism (P450 cytochromes and VDR) (40–42) and this,
at least theoretically, would oblige nutritionists, physicians, and
caregivers to ask for a reappraisal of a Consensus Panel suggesting
the proper vitamin D3 intake in relation to any of these factors
(43). Due to the extreme difficulty in achieving this goal, any
supplementation panel might be restricted to differential distribu-
tions in age clusters for both sexual groups and, anymore, to ensure
an excess of circulating 25(OH)D3 in plasma.Notwithstanding, an
excess of 25(OH)D3 may induce toxicity (44) and dampening the
role of CYP24A1 in modulating 1,25(OH)2D3 activity may cause
serious damage to kidney and calcium homeostasis (45). There-
fore, as a severe plasma 25(OH)D3 deficiency is considered a bad
prognostic marker for tumors (46), 25(OH)D3 plasma bioavail-
ability should be considered amajor bullet point in the nutritional
research of chemopreventive molecules. Yet, researchers trust the
fact that vitamin D3 should be particularly useful in cancer pre-
vention (47). Plasma 25(OH)D3 might be considered of major
important in the future, therefore, if associated with genomics and
diet habits.
A suggested work flow to assess a possible correct intake
of vitamin D3, as a supplementation factor in diet to prevent
cancer, should henceforth consider also a genomic and nutri-
tion screening, most probably according to steps described in
Table 1.
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